First in human phase I clinical study using OMV as an adjuvant for intranasal vaccinationAvacc 10® intranasal booster vaccine induces a mucosal response and no adverse eventsData will be presented at the World Vaccine Conference on April 3rd 2024 in Washington, DC BILTHOVEN, The Netherlands, March 26, 2024 (GLOBE NEWSWIRE) Intravacc, a world leader in translational research and development of preventive and therapeutic vaccines, today announced positive clinical data of a first in human (FIH)